Argentine Glaucoma Association |
|||||||||||||||
| Click here for the WGC-2009 poster describing major achievements of ArGS between 2007-2009. | |||||||||||||||
Contact information |
|||||||||||||||
|
Alejo Peyret Esmeralda 961 - 3 "D" C1007ABK Buenos Aires ARGENTINA Tel.: +54 11 43 117 139 Fax.: +54 11 431 17139 E-mail: contactenos@asag.org.ar Web site: http://www.asag.org.ar |
|||||||||||||||
Board |
|||||||||||||||
|
|||||||||||||||
Organizational structure |
|||||||||||||||
| Founding date (year) | 2001 | ||||||||||||||
| The society has statutes (bylaws) | Yes | ||||||||||||||
| The statutes address financial accountability* | Yes | ||||||||||||||
| * Is it clear how the flow of income and expense (including meetings) is and which officer or committee is responsible? | |||||||||||||||
| The board members are elected | |||||||||||||||
| New members of the board are added by cooptation** | Yes | ||||||||||||||
| ** Cooptation means officers are appointed by the leadership without an election process involving the total membership | |||||||||||||||
| The term of functioning for members of the board is | 2 year(s) | ||||||||||||||
Membership |
|||||||||||||||
| The number of members of our society is approximately | 118 | ||||||||||||||
| Our society has an annual printed report | No | ||||||||||||||
| Criteria for Membership | |||||||||||||||
|
No | ||||||||||||||
|
No | ||||||||||||||
| 17 | |||||||||||||||
|
No | ||||||||||||||
|
Yes | ||||||||||||||
|
Yes | ||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
Mission statement/goals |
|||||||||||||||
| Promote and support research and education in glaucoma in Argentina; also to support and perform national campaigns in order to detect glaucoma among general population. | |||||||||||||||
Liaisons with other organizations |
|||||||||||||||
| Liaisons with a general ophthalmological society | Yes | ||||||||||||||
| Liaisons with other organizations | No | ||||||||||||||
Guidelines |
|||||||||||||||
| Code of practice on society - Industry relationships available | No | ||||||||||||||
| Society guidelines on diagnosis and treatment of glaucoma available | No | ||||||||||||||
| Using guidelines made by an other organization | 0 | ||||||||||||||
Miscellaneous |
|||||||||||||||
| Research foundation | No | ||||||||||||||
| On-line discussion forum (e.g. AGS-net) | No | ||||||||||||||
Society program |
|||||||||||||||
| The Society program*** contains: organizing glaucoma meetings | Yes | ||||||||||||||
| *** Program = total of activities of the Glaucoma Society | |||||||||||||||
| The Society program contains: form of publication | No | ||||||||||||||
| The Society program contains: other initiatives | |||||||||||||||
| Current initiatives | - | ||||||||||||||
| Are society-sponsored fellowships or research grants available? | No | ||||||||||||||
Meeting |
|||||||||||||||
| Meeting frequency | 2-day meeting every 2 years and also 2 smaller mee | ||||||||||||||
| Time of year | - | ||||||||||||||
| Meeting attendance | |||||||||||||||
|
6 | ||||||||||||||
|
300 | ||||||||||||||
| The ratio of glaucoma specialists to generalists that attend the meeting is | Yes | ||||||||||||||
| The meeting has oral paper sessions | Yes | ||||||||||||||
| The meeting has poster sessions | Yes | ||||||||||||||
| The meeting has discussion sessions | Yes | ||||||||||||||
| Presentation / discussion time ratio | |||||||||||||||
| Presentations are on original research | No | ||||||||||||||
| Presentations are updates / reviews | Yes | ||||||||||||||
| Presentations are both original research and updates / reviews | - | ||||||||||||||
| The meetings are mono – sponsored | No | ||||||||||||||
| The meetings are multi - sponsored | Yes | ||||||||||||||
| Financial benefits from the meeting go to the Society | Yes | ||||||||||||||
| Financial benefits from the meeting go to individuals | No | ||||||||||||||
| Financial benefits from the meeting go to others | No | ||||||||||||||
Glaucoma Patient Organizations |
|||||||||||||||
| Our country has a Glaucoma Patient Organization | 0 | ||||||||||||||
| Additional remarks | |||||||||||||||